HC Wainwright assumed coverage on shares of Telix Pharmaceuticals (NASDAQ:TLX - Free Report) in a research report report published on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $23.00 price objective on the stock.
Other research analysts have also issued research reports about the company. Wedbush reaffirmed an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a report on Thursday, June 12th. William Blair reaffirmed an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, March 12th.
Get Our Latest Report on Telix Pharmaceuticals
Telix Pharmaceuticals Trading Down 2.3%
Shares of NASDAQ:TLX traded down $0.38 during trading on Thursday, reaching $16.12. The company had a trading volume of 31,814 shares, compared to its average volume of 28,587. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 0.99. The stock's fifty day moving average price is $16.86 and its 200 day moving average price is $16.96. Telix Pharmaceuticals has a fifty-two week low of $13.61 and a fifty-two week high of $30.36.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Telix Pharmaceuticals stock. ABC Arbitrage SA bought a new stake in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 26,939 shares of the company's stock, valued at approximately $451,000.
About Telix Pharmaceuticals
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Further Reading
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
